111614
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
碘油联合表阿霉素载药微球经动脉化疗栓塞治疗不可切除肝细胞癌的评估
Authors Song D, Feng X, Zhou Y, Cai Y, Xue T
Received 16 September 2025
Accepted for publication 6 December 2025
Published 12 December 2025 Volume 2025:12 Pages 2723—2733
DOI https://doi.org/10.2147/JHC.S565056
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Dr David Gerber
Dongqiang Song,1,* Xueyi Feng,2,* Yingting Zhou,1,* Yu Cai,3 Tongchun Xue1
1Department of Hepatobiliary Oncology, National Clinical Research Center for Interventional Medicine, Zhongshan Hospital, Fudan University, Shanghai, 200032, People’s Republic of China; 2Department of General Surgery, Lu’an Hospital of Anhui Medical University, Lu’an, Anhui, 237005, People’s Republic of China; 3Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, 200032, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Tongchun Xue Department of Hepatobiliary Oncology. National Clinical Research Center for Interventional Medicine, Zhongshan Hospital, Fudan University, Shanghai, 200032, People’s Republic of China, Email xue.tongchun@zs-hospital.sh.cn Yu Cai Department of Gastroenterology and Hepatology. Zhongshan Hospital, Fudan University, Shanghai, 200032, People’s Republic of China, Email cai.yu@zs-hospital.sh.cn
Purpose: To evaluate the short-term clinical efficacy, side effects and risk factors affecting the clinical effectiveness of the combination of lipidol and epirubicin-loaded drug-eluting bead transarterial chemoembolization (DEB-TACE) in the treatment of hepatocellular carcinoma (HCC).
Methods: A total of 120 patients with HCC who underwent DEB-TACE plus lipiodol treatment from December 2017 to August 2020 were enrolled. Short-term local tumor response was evaluated using mRECIST. Postoperative complications and liver function disorders were analyzed on the basis of clinical parameters.
Results: The median overall survival (OS) was 31.44 months (95% CI: 27.24– 35.46 months). According to mRISIST, the disease control rate is 75.8%. The objective response rate was 22.5%. Multivariate analysis showed that tumor size and conversion therapy were the two independent prognostic factors correlated with OS. Postoperatively, liver function showed transient changes and no grade 4 adverse events were observed. Most of the postoperative complications were characterized by post-embolism syndrome.
Conclusion: The combination of lipiodol and DEB-TACE offers effective local control and safety for patients with HCC. Lipiodol used in the DEB-TACE procedure provides several additional benefits for drug-eluting beads embolization. The synergistic effect of these two methods enhances therapeutic efficacy through dual antitumor mechanisms.
Keywords: drug-eluting bead, embolization, hepatocellular carcinoma, lipiodol, transarterial chemoembolization
1Department of Hepatobiliary Oncology, National Clinical Research Center for Interventional Medicine, Zhongshan Hospital, Fudan University, Shanghai, 200032, People’s Republic of China; 2Department of General Surgery, Lu’an Hospital of Anhui Medical University, Lu’an, Anhui, 237005, People’s Republic of China; 3Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, 200032, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Tongchun Xue Department of Hepatobiliary Oncology. National Clinical Research Center for Interventional Medicine, Zhongshan Hospital, Fudan University, Shanghai, 200032, People’s Republic of China, Email xue.tongchun@zs-hospital.sh.cn Yu Cai Department of Gastroenterology and Hepatology. Zhongshan Hospital, Fudan University, Shanghai, 200032, People’s Republic of China, Email cai.yu@zs-hospital.sh.cn
Purpose: To evaluate the short-term clinical efficacy, side effects and risk factors affecting the clinical effectiveness of the combination of lipidol and epirubicin-loaded drug-eluting bead transarterial chemoembolization (DEB-TACE) in the treatment of hepatocellular carcinoma (HCC).
Methods: A total of 120 patients with HCC who underwent DEB-TACE plus lipiodol treatment from December 2017 to August 2020 were enrolled. Short-term local tumor response was evaluated using mRECIST. Postoperative complications and liver function disorders were analyzed on the basis of clinical parameters.
Results: The median overall survival (OS) was 31.44 months (95% CI: 27.24– 35.46 months). According to mRISIST, the disease control rate is 75.8%. The objective response rate was 22.5%. Multivariate analysis showed that tumor size and conversion therapy were the two independent prognostic factors correlated with OS. Postoperatively, liver function showed transient changes and no grade 4 adverse events were observed. Most of the postoperative complications were characterized by post-embolism syndrome.
Conclusion: The combination of lipiodol and DEB-TACE offers effective local control and safety for patients with HCC. Lipiodol used in the DEB-TACE procedure provides several additional benefits for drug-eluting beads embolization. The synergistic effect of these two methods enhances therapeutic efficacy through dual antitumor mechanisms.
Keywords: drug-eluting bead, embolization, hepatocellular carcinoma, lipiodol, transarterial chemoembolization